Shares of Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS – Get Free Report) dropped 8% during mid-day trading on Wednesday. The company traded as low as $0.3910 and last traded at $0.3910. 165,870 shares traded hands during trading, a decline of 4% from the average daily volume of 173,338 shares. The stock had previously closed at $0.4250.
Analysts Set New Price Targets
A number of brokerages have commented on QCLS. Weiss Ratings lowered Mymd Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. Wall Street Zen upgraded Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
Read Our Latest Stock Report on QCLS
Mymd Pharmaceuticals Trading Down 8.0%
The stock has a market cap of $3.20 million, a PE ratio of -0.11 and a beta of 2.21. The company has a 50 day simple moving average of $0.97.
Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.
About Mymd Pharmaceuticals
TNF Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.
Further Reading
- Five stocks we like better than Mymd Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
